@inproceedings{oai:repo.qst.go.jp:00054240,
 author = {Hasegawa, Azusa and Mizoe, Junetsu and Jingu, Keiichi and Bessho, Hiroki and Morikawa, Takamichi and Kamada, Tadashi and Tsujii, Hirohiko and 長谷川 安都佐 and 溝江 純悦 and 神宮 啓一 and 別所 央城 and 森川 貴迪 and 鎌田 正 and 辻井 博彦},
 book = {Proceedings of II NIRS-CNAO Joint Symposium on Hadrontherapy (NIRS Experience)},
 issue = {229},
 month = {Mar},
 note = {To estimate the toxicity and efficacy of the clinical trials for patients with skull base and paracervical tumors treated with carbon ion radiotherapy.
A phase I/II dose escalation study for skull base and paracervical tumor was initiated in April 1997. The phase I/II dose escalation trial was performed up to the fourth-stage dose level. From April 2004, a phase II clinical trial was initiated under the Highly Advanced Medical Technology scheme with an irradiation schedule of 60.8 GyE in 16 fractions over four weeks.
At the time of analysis, there was no evidence of any serious acute or late reactions in skull base and paracervical tumors. For skull base and paracervical tumor, the carbon ion dose in excess of 57.6 GyE improves local control.},
 pages = {47--58},
 publisher = {National Institute of Radiological Sciences},
 title = {Carbon Ion Radiotherapy for Skull base and Head -and-Neck Tumors},
 volume = {NIRS-M},
 year = {2010}
}